Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer worldwide. Molecular subgroups are increasingly relevant for prognosis and therapy. In addition to established markers such as RAS, BRAF and MSI, HER2 is also coming into focus as a therapeutic target. Particularly rare histological variants such as invasive micropapillary carcinoma (IMPC) raise new questions. A recent case report from Japan describes for the first time a patient with HER2-positive colorectal carcinoma and a micropapillary component. This article summarizes the available data and discusses the clinical significance of this constellation.
Autoren
- Tanja Schliebe
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Type 2 diabetes
Smoking causes more than double the risk
- From symptom to diagnosis
Abdominal pain – Colitis
- Pathophysiology, cardiovascular consequences and metabolic interventions
Obesity accelerates cardiovascular ageing
- CKD: counteracting kidney progression and reducing the risk of CVD
Targeted intervention through a multifactorial approach
- COPD therapy
Drug therapy – Update 2025
- Atrial fibrillation: interdisciplinary effort is crucial
Managing risk factors and comorbidities in addition to rhythm control
- Casuistry
Hernia turns out to be a 25 cm long Meckel’s diverticulum
- Side effects under opioid therapy